GW Pharmaceuticals, the only company in the UK permitted to grow cannabis for medical research has submitted its latest cannabis drug, Sativex for approval in the UK and Spain. The company believes Sativex will be a boon for those suffering from multiple sclerosis.
Clinical trials have shown GW's drug Sativex, which is sprayed under the tongue, reduces spasticity in multiple sclerosis patients who do not respond adequately to existing therapies.
The drug will require further clinical trials before it can be approved for use in the USA.
http://www.reuters.com/article/rbssBiotechnology/idUSLK63796320090520
Clinical trials have shown GW's drug Sativex, which is sprayed under the tongue, reduces spasticity in multiple sclerosis patients who do not respond adequately to existing therapies.
The drug will require further clinical trials before it can be approved for use in the USA.
http://www.reuters.com/article/rbssBiotechnology/idUSLK63796320090520